With a burgeoning pipeline of drugs deeply advanced, clinical stage biopharmaceuticals company Pharmaxis (ASX: PXS) has streamlined its business with the sale of its mannitol respiratory business (MBU) and will now will focus their resources towards a much larger commercial opportunity in blood cancers haematological malignancies, aka blood cancers. The definitive sale agreement of its
Read More
Biopharmaceutical company Dimerix (ASX: DXB) has won the favour of the Paediatric Committee (PDCO) of the European Medicines Agency (EMA), as the committee has formally accepted Dimerix’s Paediatric Investigation Plan for the development of DMX-200, a potential treatment for kidney disease. The PDCO’s approval comes after a meeting on June 23, 2023, and paves the
Read More
Retail pharmacy supplier Sigma Healthcare (ASX: SIG) – the Company behind Amcal and Discount Drug Stores – has struck a deal with pharmacy giant Chemist Warehouse. The deal encompasses the supply of Pharmaceutical Benefits Scheme (PBS) medicines and healthcare products for five years, set to kick off on July 1, 2024. Sigma currently serves as
Read More
Biopharmaceutical company Starpharma (ASX: SPL) has received regulatory approval for its antiviral nasal spray product, VIRALEZE, in Malaysia. This milestone achievement grants Starpharma and its commercial partners the opportunity to market and sell the innovative product in Malaysia, a country with a population exceeding 33 million. VIRALEZE has garnered significant recognition in Asia following successful
Read More
Opioid based medications are paradoxical. Whilst an incredible pharmacologic solution to serious pain, opioids can be addictive with their overuse often proving detrimental. America is often held up as the poster child for what not to do when it comes to their opioid epidemic which has seen more than 263,000 people die from prescription opioid
Read More
